Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Two for two
September 2017
SHARING OPTIONS:

BREDA, The Netherlands & GHENT, Belgium—argenx recently achieved the second of two preclinical milestones under its collaboration with LEO Pharma. The research collaboration and exclusive license option agreement was established in May 2015, focused on the development and commercialization of ARGX-112. argenx is responsible for all research and development activities up to a first filing by LEO Pharma for clinical trial application approval, and LEO has an exclusive option for a worldwide, exclusive license to the program to develop and commercialize products for inflammatory skin disorders. argenx also has the potential to receive additional regulatory and clinical milestone payments worth up to roughly €100 million and royalties on net sales, in addition to the previously achieved milestones.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.